INTERACTION BETWEEN THE RETINOBLASTOMA PROTEIN AND THE ONCOPROTEIN MDM2

被引:549
|
作者
XIAO, ZX
CHEN, JD
LEVINE, AJ
MODJTAHEDI, N
XING, J
SELLERS, WR
LIVINGSTON, DM
机构
[1] HARVARD UNIV,SCH MED,BOSTON,MA 02115
[2] PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544
关键词
D O I
10.1038/375694a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
INACTIVATION of tumour-suppressor genes leads to deregulated cell proliferation and is a key factor in human tumorigenesis. Both p53 and retinoblastoma genes are frequently mutated in human cancers(1,2), and the simultaneous inactivation of RB and p53 is frequently observed in a variety of naturally occurring human tumours(3). Furthermore, three distinct DNA tumour virus groups papovaviruses, adenoviruses and human papillomaviruses-transform cells by targeting and inactivating certain functions of both the p53 and retinoblastoma proteins(1,2). The cellular oncoprotein, Mdm2, binds to and downmodulates p53 function(4-6); its human homologue, MDM2, is amplified in certain human tumours, including sarcomas(7-9) and gliomas(10). Overproduction of Mdm2 is both tumorigenic(4) and capable of immortalizing primary rat embryo fibroblasts(11). Here we show that MDM2 interacts physically and functionally with pRB and, as with p53, inhibits pRB growth regulatory function. Therefore, both pRB and p53 can be subjected to negative regulation by the product of a single cellular proto-oncogene.
引用
收藏
页码:694 / 698
页数:5
相关论文
共 50 条
  • [21] Tumorogenesis and mdm2 protein
    Flores, C
    Sobrevia, L
    [J]. REVISTA MEDICA DE CHILE, 2000, 128 (05) : 539 - 546
  • [22] MDM2 GENE ALTERATIONS AND MDM2 PROTEIN EXPRESSION IN BREAST CARCINOMAS
    MARCHETTI, A
    BUTTITTA, F
    GIRLANDO, S
    DALLAPALMA, P
    PELLEGRINI, S
    FINA, P
    DOGLIONI, C
    BEVILACQUA, G
    BARBARESCHI, M
    [J]. JOURNAL OF PATHOLOGY, 1995, 175 (01): : 31 - 38
  • [23] Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light
    Hansen, Mickel J.
    Feringa, Femke M.
    Kobauri, Piermichele
    Szymanski, Wiktor
    Medema, Rene H.
    Feringa, Ben L.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2018, 140 (41) : 13136 - 13141
  • [24] Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
    Stoll, R
    Renner, C
    Hansen, S
    Palme, S
    Klein, C
    Belling, A
    Zeslawski, W
    Kamionka, M
    Rehm, T
    Mühlhahn, P
    Schumacher, R
    Hesse, F
    Kaluza, B
    Voelter, W
    Engh, RA
    Holak, TA
    [J]. BIOCHEMISTRY, 2001, 40 (02) : 336 - 344
  • [25] MDM2 Targeting sd-rxRNA® for Retinoblastoma Therapy
    Stachelek, Kevin
    Cardia, James
    Qi, Donglai
    Singh, Hardeep Pal
    Pandarinathan, Lakshmipathi
    Holton, Katherine
    Bulock, Karen
    Pavco, Pamela A.
    Cobrinik, David
    Byrne, Michael
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [26] MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein
    Sdek, P
    Ying, HQ
    Chang, DLF
    Qiu, W
    Zheng, HW
    Touitou, R
    Allday, MJ
    Xiao, ZXJ
    [J]. MOLECULAR CELL, 2005, 20 (05) : 699 - 708
  • [27] Retinoblastoma and protein expression of P14ARF, MDM2 and P53
    Carvalho, L. M.
    Alarcao, A. M.
    Teixeira, C. L.
    Fonseca, M. C.
    Proenca, R. D.
    [J]. HISTOPATHOLOGY, 2010, 57 : 210 - 210
  • [28] β-arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2
    Wang, P
    Gao, H
    Ni, YX
    Wang, BB
    Wu, YL
    Ji, LL
    Qin, LH
    Ma, L
    Pei, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) : 6363 - 6370
  • [29] A novel oncoprotein Pirh2: rising from the shadow of MDM2
    Wang, Zhihao
    Yang, Bo
    Dong, Lanlan
    Peng, Biwen
    He, Xiaohua
    Liu, Wanhong
    [J]. CANCER SCIENCE, 2011, 102 (05): : 909 - 917
  • [30] Molecular mechanism of the interaction between MDM2 and p53
    Schon, O
    Friedler, A
    Bycroft, M
    Freund, SMV
    Fersht, AR
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2002, 323 (03) : 491 - 501